Opendata, web and dolomites

EuroNeurotrophin SIGNED

A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EuroNeurotrophin project word cloud

Explore the words cloud of the EuroNeurotrophin project. It provides you a very rough idea of what is the project "EuroNeurotrophin" about.

molecules    comprehend    cure    worldwide    prohibitive    mimetics    biological    neurotrophin    therapeutic    drug    neurogenesis    motivated    function    12    poor    idea    collaborations    beneficiaries    pathogenesis    nd    builds    molecular    render    demonstrated    enriched    drugs    companies    tackle    market    societies    fail    deep    clinical    collectively    point    translation    actions    patented    survival    euroneurotrophin    penetration    molecule    mnd    expertise    groups    nhrf    small    conduct    pd    forth    discovery    neurons    designed    neuroprotection    stability    diseases    neurodegenerative    ad    treatments    emphasise    doctoral    interrogate    seminal    exists    limitation    ms    possess    neurotrophins    specialists    candidate    complementary    network    shown    probes    collaborative    stage    single    training    therapies    consists    successful    first    skills    preclinical    translate    academic    private    of    tissue    14    skilled    profiles    pharmacokinetic    accelerate    als   

Project "EuroNeurotrophin" data sheet

The following table provides information about the project.

Coordinator
ETHNIKO IDRYMA EREVNON 

Organization address
address: VAS KONSTANTINOU 48
city: ATHINA
postcode: 11635
website: www.eie.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Total cost 3˙555˙758 €
 EC max contribution 3˙555˙758 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-ETN
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ETHNIKO IDRYMA EREVNON EL (ATHINA) coordinator 484˙773.00
2    AvantiCell Science Ltd UK (AYR) participant 546˙575.00
3    HITS GGMBH DE (HEIDELBERG) participant 498˙432.00
4    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) participant 484˙773.00
5    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 273˙287.00
6    UNIVERSITE DE CAEN NORMANDIE FR (CAEN CEDEX 5) participant 262˙875.00
7    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 258˙061.00
8    STICHTING VU NL (AMSTERDAM) participant 255˙374.00
9    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 249˙216.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 242˙386.00
11    ACCELOPMENT AG CH (ZUERICH) partner 0.00
12    Innovative Technologies in Biological Systems ES (Derio) partner 0.00
13    Novartis (Ελλάς) Α.Ε.Β.Ε. EL (Metamorphosis) partner 0.00
14    PANEPISTIMIO KRITIS EL (RETHIMNO) partner 0.00
15    Peakdale Molecular Limited UK (Chapel-en-le-Frith) partner 0.00
16    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) partner 0.00
17    Ventac A/S DK (Hoersholm) partner 0.00

Map

 Project objective

Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive. The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation. This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies. The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.

 Publications

year authors and title journal last update
List of publications.
2020 Athanasios Ziogas, Tomoki Maekawa, Johannes R. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis, Vasileia Ismini Alexaki
DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1
published pages: 1214-1224, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900746
The Journal of Immunology 204/5 2020-03-11
2019 Canelif Yilmaz, Kanelina Karali, Georgia Fodelianaki, Achille Gravanis, Triantafyllos Chavakis, Ioannis Charalampopoulos, Vasileia Ismini Alexaki
Neurosteroids as regulators of neuroinflammation
published pages: 100788, ISSN: 0091-3022, DOI: 10.1016/j.yfrne.2019.100788
Frontiers in Neuroendocrinology 55 2020-03-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURONEUROTROPHIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURONEUROTROPHIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

WON (2019)

Wideband Optical Networks

Read More